WO2007140181A3 - Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist - Google Patents

Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist Download PDF

Info

Publication number
WO2007140181A3
WO2007140181A3 PCT/US2007/069440 US2007069440W WO2007140181A3 WO 2007140181 A3 WO2007140181 A3 WO 2007140181A3 US 2007069440 W US2007069440 W US 2007069440W WO 2007140181 A3 WO2007140181 A3 WO 2007140181A3
Authority
WO
WIPO (PCT)
Prior art keywords
adenosine
receptor antagonist
uptake inhibitor
combination therapy
selective
Prior art date
Application number
PCT/US2007/069440
Other languages
French (fr)
Other versions
WO2007140181A2 (en
Inventor
Edward Leung
Original Assignee
King Pharmaceuticals Res & Dev
Edward Leung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Res & Dev, Edward Leung filed Critical King Pharmaceuticals Res & Dev
Publication of WO2007140181A2 publication Critical patent/WO2007140181A2/en
Publication of WO2007140181A3 publication Critical patent/WO2007140181A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Abstract

The present invention relates to a pharmaceutical combination comprising an adenosine uptake inhibitor, or a pharmaceutically acceptable salt thereof, and a non-selective adenosine receptor antagonist, or a pharmaceutically acceptable salt thereof, for the treatment of cancer diseases, and inflammatory disorders such as rheumatoid arthritis, osteoarthritis, psoriasis and dry eye syndrome, through stimulation of the adenosine A3 receptor.
PCT/US2007/069440 2006-05-26 2007-05-22 Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist WO2007140181A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80911206P 2006-05-26 2006-05-26
US60/809,112 2006-05-26

Publications (2)

Publication Number Publication Date
WO2007140181A2 WO2007140181A2 (en) 2007-12-06
WO2007140181A3 true WO2007140181A3 (en) 2008-08-14

Family

ID=38779321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/069440 WO2007140181A2 (en) 2006-05-26 2007-05-22 Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist

Country Status (1)

Country Link
WO (1) WO2007140181A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9254289B2 (en) 2013-03-13 2016-02-09 Remedeye Inc. Methods for treating eye disorders using dipyridamole
SI3601296T1 (en) 2017-03-30 2022-10-28 iTeos Belgium SA 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
US11376255B2 (en) 2018-09-11 2022-07-05 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
BE1026612B1 (en) * 2018-09-27 2020-07-02 Iteos Therapeutics S A USE OF AN ENT FAMILY CARRIER INHIBITOR IN THE TREATMENT OF CANCER AND COMBINATION THEREOF WITH AN ADENOSINE RECEPTOR ANTAGONIST
WO2020065036A1 (en) * 2018-09-27 2020-04-02 Iteos Therapeutics S.A. Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064448A1 (en) * 1999-04-27 2000-11-02 Board Of Regents, The University Of Texas System A composition and method for treatment of cerebral ischemia
WO2002022127A1 (en) * 2000-09-13 2002-03-21 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
US20030013633A1 (en) * 1999-06-07 2003-01-16 Rima Kaddurah-Daouk Use of molecules that modulate an energy related associated state

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064448A1 (en) * 1999-04-27 2000-11-02 Board Of Regents, The University Of Texas System A composition and method for treatment of cerebral ischemia
US20030013633A1 (en) * 1999-06-07 2003-01-16 Rima Kaddurah-Daouk Use of molecules that modulate an energy related associated state
WO2002022127A1 (en) * 2000-09-13 2002-03-21 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders

Also Published As

Publication number Publication date
WO2007140181A2 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
WO2008094737A3 (en) Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
WO2008095086A3 (en) Topiramate plus naltrexone for the treatment of addictive disorders
UA100116C2 (en) Preventive or remedy for inflammatory disease
WO2008064321A3 (en) Methods of treating chronic inflammatory diseases using a gm-csf antagonist
CL2008003056A1 (en) Compounds derived from 3-phenyl-imidazo [1,2-a] pyridines; pharmaceutical composition; process for its preparation, useful as inhibitors of alk-5 or alk-4 in the treatment of inflammatory or obstructive diseases of the respiratory tract, cancer, muscular diseases, skeletal disorders
WO2007150025A3 (en) Purinone derivatives as hm74a agonists
WO2007048070A3 (en) Pyrrolo-pyridine derivatives for the treatment of cancer diseases
WO2006058868A3 (en) Substituted pteridines for treating inflammatory diseases
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
UA85597C2 (en) Quaternary salt ccr2 antagonists
EP2322219A3 (en) Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
WO2008156142A1 (en) Novel malonic acid sulfonamide derivative and pharmaceutical use thereof
WO2005082893A3 (en) Histamine h3 receptor antagonists, preparation and therapeutic uses
WO2007126934A3 (en) Amidoethylthioether orexin receptor antagonists
WO2007128802A3 (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
WO2006092741A3 (en) Treatment of inflammatory disorders with praziquantel
WO2012048129A3 (en) Inhibitors of polo-like kinase
WO2008077557A8 (en) 8-ethinylxanthine derivatives as selective a2a receptor antagonists
WO2008086014A3 (en) Bis-aryl amide derivatives useful for the treatment of cancer
WO2006058867A3 (en) Substituted pteridines for the treatment of inflammatory diseases
WO2009002423A3 (en) Polycyclic guanine derivatives and use thereof
MX346186B (en) Protein kinase inhibitors.
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07762277

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07762277

Country of ref document: EP

Kind code of ref document: A2